utrophin Antibody (MANCHO7): sc-81557

Utrophin Antibody (MANCHO7) is a mouse monoclonal IgG2a antibody that detects utrophin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Utrophin is a crucial structural protein that shares significant homology with dystrophin and plays a vital role in stabilizing the muscle cell membrane by anchoring the cytoskeleton to the plasma membrane. Anti-utrophin antibody (MANCHO7) recognizes a protein predominantly localized to the inner surface of the plasma membrane in muscle and brain tissues, where utrophin is essential for maintaining cellular integrity and function. Utrophin′s importance lies in its ability to compensate for the loss of dystrophin in conditions such as Duchenne muscular dystrophy, where dystrophin deficiency leads to severe muscle degeneration. Notably, utrophin can interact with various dystrophin-associated proteins, and utrophin upregulation has been shown to mitigate the pathological effects of dystrophin loss, making utrophin a potential therapeutic target for muscular dystrophies. Anti-utrophin antibody (MANCHO7) serves as an invaluable tool for researchers studying muscle biology and the molecular mechanisms underlying muscular dystrophies, providing insights into utrophin′s role in cellular architecture and disease progression.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

utrophin Antibody (MANCHO7) References:

1. Translational regulation of utrophin by miRNAs.  |  Basu, U., et al. 2011. PLoS One. 6: e29376. PMID: 22216264
2. Concordant utrophin upregulation in phenotypically discordant DMD/BMD brothers.  |  Vainzof, M., et al. 2016. Neuromuscul Disord. 26: 197-200. PMID: 26851826
3. The utrophin-beta 2 syntrophin complex regulates adipocyte lipid droplet size independent of adipogenesis.  |  Krautbauer, S., et al. 2019. Mol Cell Biochem. 452: 29-39. PMID: 30014220
4. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.  |  Guiraud, S., et al. 2019. Hum Mol Genet. 28: 2189-2200. PMID: 30990876
5. High-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy.  |  Loro, E., et al. 2020. Sci Rep. 10: 2132. PMID: 32034254
6. Cardio-respiratory and phenotypic rescue of dystrophin/utrophin-deficient mice by combination therapy.  |  Lin, C., et al. 2022. EMBO Rep. 23: e53955. PMID: 35393769
7. Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy.  |  Chatzopoulou, M., et al. 2022. Bioorg Med Chem. 69: 116812. PMID: 35772287
8. Utrophin localization in normal and dystrophin-deficient heart.  |  Pons, F., et al. 1994. Circulation. 90: 369-74. PMID: 8026021
9. Subtle neuromuscular defects in utrophin-deficient mice.  |  Grady, RM., et al. 1997. J Cell Biol. 136: 871-82. PMID: 9049252
10. Molecular mechanisms and putative signalling events controlling utrophin expression in mammalian skeletal muscle fibres.  |  Gramolini, AO. and Jasmin, BJ. 1998. Neuromuscul Disord. 8: 351-61. PMID: 9713851

The preferred utrophin antibody is utrophin Antibody (8A4): sc-33700.